Interdepartmental Center of Research in Molecular Medicine-CIRMC, University of Pavia, 27100 Pavia, Italy.
Mediators Inflamm. 2012;2012:874149. doi: 10.1155/2012/874149. Epub 2012 Feb 13.
Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.
一些降压药物还具有肾脏保护和抗炎作用，这些作用超出了其对血压的影响。有人提出，微量白蛋白尿和肾小球滤过率（GFR）与循环中可溶性受体（晚期糖基化终产物的可溶性受体，sRAGE）的水平有关。在本分析中，我们使用 TALENT 研究的数据评估了高血压和高心血管风险患者的可溶性受体（晚期糖基化终产物的可溶性受体，sRAGE）血浆水平，这些患者接受硝苯地平-替米沙坦联合治疗。硝苯地平-替米沙坦治疗 24 周后，可显著降低平均收缩压和舒张压，且 sRAGE 血浆浓度显著升高。我们得出结论，在早期肾病的高血压患者中，sRAGE 浓度不受微量白蛋白尿或 GFR 的影响。长期使用硝苯地平-替米沙坦联合治疗可能具有有益作用，可增加 sRAGE 血浆水平，从而发挥抗动脉粥样硬化和抗炎作用。
